Abstract:Editor-in-Chief, reviews two of the most remarkable papers published in The Chinese Journal of Cardiology (CJC). Transcatheter aortic valve replacement (TAVR) has become an established and increasingly used approach for the management of severe symptomatic aortic stenosis (AS) or regurgitation throughout the surgical risk spectrum, showing similar, or even superior outcomes compared with standard surgical aortic valve replacement. Despite an iteration in TAVR device technologies and improved patient selection and management through the multidisciplinary heart teams, challenges, and controversies exist regarding the balancing of ischaemic and bleeding risks in these patients and the optimal antithrombotic regimens to adopt after TAVR are still unclear. This was recently reported in the CJC with a contribution entitled ‘One-year follow-up results of atrial fibrillation (AF) patients who undergoing transcatheter aortic valve implantation’ by Prof. Yaling Han and colleagues from General Hospital of Northern Theater Command. This is a single-centre retrospective study. A total of 115 patients with severe AS who were admitted to the hospital from May 2016 to November 2020 and successfully received TAVR were included. According to the absence or presence of AF pre-TAVR, they were divided into the AF group (n= 21) and the non-AF group (n= 94). The patients were followed up for postoperative antithrombotic treatment and the occurrence of the net adverse clinical and cerebrovascular events (NACCEs) at 12 months post-TAVR, including cardiac death, readmission to hospital for heart failure, non-fatal myocardial infarction, ischaemic stroke, and major bleeding [Bleeding Academic Research Consortium (BARC) levels 3–5]. Among the 115 selected patients, age was (73.8+ 6.9) years, there were 63 males. In terms of postoperative antithrombotic therapy, 48.9% (46/94) of the patients in the non-AF group received monotherapy and 47.9% (45/94) received dual antiplatelet therapy (DAPT). In the AF group, 47.6% (10/21) received anticoagulants and 33.3% (7/21) received DAPT. The proportion of patients in the AF group taking non-vitamin K antagonist oral anticoagulants (NOACs) was higher than that in the non-AF group [38.1% (8/21) vs. 2.1% (2/94), P, 0.001]. During the 12 months follow-up, the incidence of NACCE after TAVR was 14.3% (3/21) in the AF group, which was numerically higher than that in the non-AF group [6.4% (6/94)], while the difference was not statistically significant (P= 0.441, Table 1). The incidence of major bleeding was significantly higher in the AF group than in the non-AF group [9.5% (2/21) vs. 0.0%, P= 0.032, Table 1]. Univariate logistic regression analysis showed that hypertension was associated with the risk of NACCE (OR= 8.308, P= 0.050), while AF was not associated with the risk of NACCE (P= 0.235). Therefore, the incidence of severe bleeding after TAVR is higher in

Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document

Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing TAVR

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding after TAVR

Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study

Meta-analysis of Predictors of Early Severe Bleeding in Patients Who Underwent Transcatheter Aortic Valve Implantation.

Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution

Hematological Complications From Transcatheter Aortic Valve Replacement (TAVR): Recognition and Treatment.

Determining risk factors for vascular and bleeding complications after TAVR using CT angiography

Evaluation of Current Practices in Transcatheter Aortic Valve Implantation: the WRITTEN (worldwide TAVI ExperieNce) Survey.

Vascular Complications and Bleeding After Transfemoral TAVR With Surgical Versus Percutaneous Approach: A Contemporary Prospective Study

Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients

The Transcatheter Aortic Valve Replacement-Conduction Study: The Value of the His-Ventricular Interval in Risk Stratification for Post-TAVR Atrioventricular-Block

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement

Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study

Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions

PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN DISEASE IN HIGH BLEEDING RISK: OUTCOMES FROM A SUBANALYSIS OF THE DELTA 2 REGISTRY

Clinical impact of Academic Research Consortium for High Bleeding-Risk scores on clinical outcomes in patients with stable coronary artery disease undergoing percutaneous coronary intervention

Red blood cell transfusion and mortality after transcatheter aortic valve implantation via transapical approach: A propensity-matched comparison from the TRITAVI registry

Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial

Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient-Level Study